vipoglanstat

Vipoglanstat (formerly known as GS-248, OX-MPI, and BI-1029539) is an oral small molecule drug developed by Gesynta Pharma for the treatment of chronic inflammatory diseases. Its primary mechanism of action is the selective inhibition of microsomal prostaglandin E2 synthase 1 (mPGES-1), an enzyme involved in the production of pro-inflammatory prostaglandin E2 (PGE2). By blocking mPGES-1, vipoglanstat reduces inflammation and has vasodilatory effects that may improve blood flow. The drug has been evaluated in phase II clinical trials for systemic sclerosis (scleroderma), particularly targeting Raynaud’s phenomenon secondary to this disease. Although it demonstrated a favorable safety profile and potent target engagement in these studies, no significant symptomatic benefit was observed in systemic sclerosis patients. As a result, development efforts are also being directed toward other indications such as endometriosis[1][3][4][5][6][7].

Other names

vipoglanstat